Zolbetuximab not checked

Astellas · IMAB362

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 2 trial completes
Trials
8 active
12 in total · 6 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“Participants will receive an IV infusion of zolbetuximab once every 2 or 3 weeks.”In the company’s words, NCT07829757 on ClinicalTrials.gov
Tested for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer (4 trials), Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer (4 trials), Metastatic Gastric Adenocarcinoma or Cancer (4 trials), Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma (4 trials), Metastatic Pancreatic Adenocarcinoma (2 trials), Pancreatic Cancer, Metastatic Pancreatic Cancer, Pharmacokinetics of Zolbetuximab and 4 more
Main trialPhase 4
“There is an unmet medical need to treat people with advanced cancer in the stomach and the junction area where the stomach joins the food pipe. These conditions are known as advanced or stomach (gastric) cancer and advanced gastroesophageal junction cancer (GEJ cancer for short). Zolbetuximab is an approved treatment in many countries for people with advanced stomach cancer and advanced GEJ cancer. Some people with these cancers have a protein called Claudin 18.2 on their tumor but they do not have a protein called HER2 (human epidermal growth factor receptor 2) on their surface…”In the company’s words, NCT07829757 on ClinicalTrials.gov
Other names
Claudiximab · IMAB362 · Vyloy

Other drugs for Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer

All 368 drugs for Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials12

TrialPhaseCompletesWhat it tests
Phase 4Not yet recruiting 31 Jul 2029 A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer
Phase 3Active, not recruiting 9 Sep 2022 A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
Phase 3Active, not recruiting 25 Oct 2022 A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
Phase 3Recruiting 30 Sep 2028 A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Phase 2Active, not recruiting 31 Oct 2026 A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
Phase 2Active, not recruiting 30 Jun 2027 A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
Phase 1Active, not recruiting 31 Dec 2026 A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer
Phase 2Completed 13 Aug 2015 Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer
Phase 2Completed 31 Jan 2019 Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer
Phase 1Completed 31 May 2010 Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer
Phase 1Completed 22 Jan 2021 A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
Phase 2Authorised not given Phase II RAINSPOT: a multicentric open label trial of Zolbetuximab-Paclitaxel-Ramucirumab in second line setting for CLDN18.2 positive gastro-esophageal adenocarcinoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Zolbetuximab

Following is part of Solo: you see every change to Zolbetuximab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in